FDA Fast-Tracks Review of 3 New Immunotherapy Options for Esophageal Cancer Patients
The U.S. Food & Drug Administration has granted Priority Review for the use of immunotherapies in three new designations for [...]
The U.S. Food & Drug Administration has granted Priority Review for the use of immunotherapies in three new designations for [...]
The U.S. Food & Drug Administration has approved a new therapy for adult patients with locally advanced or metastatic HER2+ [...]
The latest statistics released by the American Cancer Society projects that fewer Americans will die of Esophageal Cancer in 2021 [...]
Despite the challenges of 2020, progress was achieved in the battle to end Esophageal Cancer - much of it thanks [...]
Findings of three studies important to Esophageal Cancer patients were presented at the 2020 ESMO (European Society of Medical Oncology) [...]
Results of a clinical study called PANGEA (Personalized ANtibodies for GastroEsophageal Adenocarcinoma) found survival benefits for patients when compared to [...]
A message from ECAN's founder: My husband’s birthday came this week. And this year, for the first time since he [...]
The early results of two large, Phase III clinical trials of the immunotherapy Opdivo (nivolumab) showed significant survival benefits for [...]
The familial connection is one of the Strongest Indicators of Risk according to Experts. ECAN spoke with the Leading Researcher [...]
First Time the FDA has given Breakthrough Designation for a Device Targeting Diseases of the Esophagus. Lucid Diagnostics' EsoGuard™ Esophageal [...]